Asia Pacific Rapid Acting Insulin Market By Product Type (Insulin Lispro, Insulin Aspart and Insulin Glulisine), By Indication (Type 2 Diabetes and Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Rapid Acting Insulin Market
The Asia Pacific Rapid Acting Insulin Market would witness market growth of 6.9% CAGR during the forecast period (2021-2027). The growth of the rapid-acting insulin market is expected to be fuelled due to various factors. An unhealthy and sedentary lifestyle is one of the prime factors which is creating profitable growth opportunities for the global rapid-acting insulin market during the forecast period. Along with this, other aspects like family diabetic history, unhealthy eating habits, and higher insulin resistance will augment the number of diabetes patients across the world. This would further support the demand and growth of rapid-acting insulin in the upcoming years.
Moreover, the global rapid-acting insulin market would be driven by the growing number of research and development (R&D) activities for human recombinant insulin. Leading players operating in the rapid-acting insulin market are introducing unique and advanced rapid-acting insulins with an aim to cater the growing market demand. As per The Australian Centre for Complex Integrated Surgical Solutions (ACCISS) 2016 report, pharmaceutical giants like Sanofi, Novo Nordisk, and Eli Lily are currently dominating the rapid-acting insulin market. This offers momentum and possibility for the development of the rapid-acting insulin market.
The China market dominated the Asia Pacific Online Providers Market by Country in 2020, and would continue to be a dominant market till 2027. The Japan market is experiencing a CAGR of 8.7% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 8.6% during (2021 - 2027).
The Insulin Lispro market dominated the Malaysia Rapid Acting Insulin Market by Product Type in 2020, thereby, achieving a market value of $63.3 Million by 2027. The Insulin Aspart market is expected to witness a CAGR of 8.7% during (2021 - 2027).
Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Insulin Lispro
- Insulin Aspart
- Insulin Glulisine
- Type 2 Diabetes
- Type 1 Diabetes
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
- South Korea
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly and Company
- Adocia SA
- Biocon Limited
- Gan & Lee Pharmaceuticals
- Geropharm LLC
- Wockhardt Ltd.
- MannKind Corporation
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free